title: Peptide receptor radionuclide therapy: an overview.
abstract: Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.
authors.affiliation: 1 Isotope Production and Applications Division, Bhabha Atomic Research Centre , Mumbai, India .
authors.forename: Ashutosh
authors.initials: A
authors.lastname: Dash
authors.forename: Sudipta
authors.initials: S
authors.lastname: Chakraborty
authors.forename: Maroor Raghavan Ambikalmajan
authors.initials: MR
authors.lastname: Pillai
authors.forename: Furn F Russ
authors.initials: FF
authors.lastname: Knapp
mesh_terms: D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy*; D011868:Radioisotopes / Q000494:pharmacology* / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000494:pharmacology* / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000008:administration & dosage*
chemical_list: D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018000:Receptors, Peptide
keywords: 111In; 177Lu; 90Y; CCK; GLP; NT; PRRT; RGD; VIP; angiogenesis; bombesin; cytotoxic; neuroendocrine tumour; radionuclide therapy; somatostatin; therapeutic radionuclide